Showing items 1 - 3 of 3

Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021 : a systematic analysis from the Global Burden of Disease Study 2021

- Bender, Rose, Sirota, Sarah, Swetschinski, Lucien, Dominguez, Regina-Mae, Novotney, Amanda, Wool, Eve, Ikuta, Kevin, Vongpradith, Avina, Rogowski, Emma, Doxey, Matthew, Troeger, Christopher, Albertson, Samuel, Ma, Jianing, He, Jiawei, Maass, Kelsey, Simões, Eric, Abdoun, Meriem, Aziz, Jeza, Abdulah, Deldar, Rumeileh, Samir, Abualruz, Hasan, Aburuz, Salahdein, Adepoju, Abiola, Adha, Rishan, Adikusuma, Wirawan, Adra, Saryia, Afraz, Ali, Aghamiri, Shahin, Agodi, Antonella, Ahmadzade, Amir, Banik, Biswajit

  • Authors: Bender, Rose , Sirota, Sarah , Swetschinski, Lucien , Dominguez, Regina-Mae , Novotney, Amanda , Wool, Eve , Ikuta, Kevin , Vongpradith, Avina , Rogowski, Emma , Doxey, Matthew , Troeger, Christopher , Albertson, Samuel , Ma, Jianing , He, Jiawei , Maass, Kelsey , Simões, Eric , Abdoun, Meriem , Aziz, Jeza , Abdulah, Deldar , Rumeileh, Samir , Abualruz, Hasan , Aburuz, Salahdein , Adepoju, Abiola , Adha, Rishan , Adikusuma, Wirawan , Adra, Saryia , Afraz, Ali , Aghamiri, Shahin , Agodi, Antonella , Ahmadzade, Amir , Banik, Biswajit
  • Date: 2024
  • Type: Text , Journal article
  • Relation: The Lancet Infectious Diseases Vol. 24, no. 9 (2024), p. 974-1002
  • Full Text:
  • Reviewed:
  • Description: Background: Lower respiratory infections (LRIs) are a major global contributor to morbidity and mortality. In 2020–21, non-pharmaceutical interventions associated with the COVID-19 pandemic reduced not only the transmission of SARS-CoV-2, but also the transmission of other LRI pathogens. Tracking LRI incidence and mortality, as well as the pathogens responsible, can guide health-system responses and funding priorities to reduce future burden. We present estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 of the burden of non-COVID-19 LRIs and corresponding aetiologies from 1990 to 2021, inclusive of pandemic effects on the incidence and mortality of select respiratory viruses, globally, regionally, and for 204 countries and territories. Methods: We estimated mortality, incidence, and aetiology attribution for LRI, defined by the GBD as pneumonia or bronchiolitis, not inclusive of COVID-19. We analysed 26 259 site-years of mortality data using the Cause of Death Ensemble model to estimate LRI mortality rates. We analysed all available age-specific and sex-specific data sources, including published literature identified by a systematic review, as well as household surveys, hospital admissions, health insurance claims, and LRI mortality estimates, to generate internally consistent estimates of incidence and prevalence using DisMod-MR 2.1. For aetiology estimation, we analysed multiple causes of death, vital registration, hospital discharge, microbial laboratory, and literature data using a network analysis model to produce the proportion of LRI deaths and episodes attributable to the following pathogens: Acinetobacter baumannii, Chlamydia spp, Enterobacter spp, Escherichia coli, fungi, group B streptococcus, Haemophilus influenzae, influenza viruses, Klebsiella pneumoniae, Legionella spp, Mycoplasma spp, polymicrobial infections, Pseudomonas aeruginosa, respiratory syncytial virus (RSV), Staphylococcus aureus, Streptococcus pneumoniae, and other viruses (ie, the aggregate of all viruses studied except influenza and RSV), as well as a residual category of other bacterial pathogens. Findings: Globally, in 2021, we estimated 344 million (95% uncertainty interval [UI] 325–364) incident episodes of LRI, or 4350 episodes (4120–4610) per 100 000 population, and 2·18 million deaths (1·98–2·36), or 27·7 deaths (25·1–29·9) per 100 000. 502 000 deaths (406 000–611 000) were in children younger than 5 years, among which 254 000 deaths (197 000–320 000) occurred in countries with a low Socio-demographic Index. Of the 18 modelled pathogen categories in 2021, S pneumoniae was responsible for the highest proportions of LRI episodes and deaths, with an estimated 97·9 million (92·1–104·0) episodes and 505 000 deaths (454 000–555 000) globally. The pathogens responsible for the second and third highest episode counts globally were other viral aetiologies (46·4 million [43·6–49·3] episodes) and Mycoplasma spp (25·3 million [23·5–27·2]), while those responsible for the second and third highest death counts were S aureus (424 000 [380 000–459 000]) and K pneumoniae (176 000 [158 000–194 000]). From 1990 to 2019, the global all-age non-COVID-19 LRI mortality rate declined by 41·7% (35·9–46·9), from 56·5 deaths (51·3–61·9) to 32·9 deaths (29·9–35·4) per 100 000. From 2019 to 2021, during the COVID-19 pandemic and implementation of associated non-pharmaceutical interventions, we estimated a 16·0% (13·1–18·6) decline in the global all-age non-COVID-19 LRI mortality rate, largely accounted for by a 71·8% (63·8–78·9) decline in the number of influenza deaths and a 66·7% (56·6–75·3) decline in the number of RSV deaths. Interpretation: Substantial progress has been made in reducing LRI mortality, but the burden remains high, especially in low-income and middle-income countries. During the COVID-19 pandemic, with its associated non-pharmaceutical interventions, global incident LRI cases and mortality attributable to influenza and RSV decline substantially. Expanding access to health-care services and vaccines, including S pneumoniae, H influenzae type B, and novel RSV vaccines, along with new low-cost interventions against S aureus, could mitigate the LRI burden and prevent transmission of LRI-causing pathogens. Funding: Bill & Melinda Gates Foundation, Wellcome Trust, and Department of Health and Social Care (UK). © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license **Please note that there are multiple authors for this article therefore only the name of the first 30 including Federation University Australia affiliate "Biswajit Banik” is provided in this record**

Global, regional, and national burden of meningitis and its aetiologies, 1990–2019 : a systematic analysis for the global burden of disease study 2019

- Wunrow, Han, Bender, Rose, Vongpradith, Avina, Sirota, Sarah, Swetschinski, Lucien, Novotney, Amanda, Gray, Authia, Ikuta, Kevin, Sharara, Fablina, Wool, Eve, Aali, Amirali, Abd-Elsalam, Sherief, Abdollahi, Ashkan, Abdul Aziz, Jeza, Abidi, Hassan, Aboagye, Richard, Abolhassani, Hassan, Abu-Gharbieh, Eman, Adamu, Lawan, Adane, Tigist, Addo, Isaac, Adegboye, Oyelola, Adekiya, Tayo, Adnan, Mohammad, Adnani, Qorinah, Afzal, Saira, Aghamiri, Shahin, Aghdam, Zahra, Agodi, Antonella, Rahman, Muhammad Aziz

  • Authors: Wunrow, Han , Bender, Rose , Vongpradith, Avina , Sirota, Sarah , Swetschinski, Lucien , Novotney, Amanda , Gray, Authia , Ikuta, Kevin , Sharara, Fablina , Wool, Eve , Aali, Amirali , Abd-Elsalam, Sherief , Abdollahi, Ashkan , Abdul Aziz, Jeza , Abidi, Hassan , Aboagye, Richard , Abolhassani, Hassan , Abu-Gharbieh, Eman , Adamu, Lawan , Adane, Tigist , Addo, Isaac , Adegboye, Oyelola , Adekiya, Tayo , Adnan, Mohammad , Adnani, Qorinah , Afzal, Saira , Aghamiri, Shahin , Aghdam, Zahra , Agodi, Antonella , Rahman, Muhammad Aziz
  • Date: 2023
  • Type: Text , Journal article
  • Relation: The Lancet Neurology Vol. 22, no. 8 (2023), p. 685-711
  • Full Text:
  • Reviewed:
  • Description: Background: Although meningitis is largely preventable, it still causes hundreds of thousands of deaths globally each year. WHO set ambitious goals to reduce meningitis cases by 2030, and assessing trends in the global meningitis burden can help track progress and identify gaps in achieving these goals. Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we aimed to assess incident cases and deaths due to acute infectious meningitis by aetiology and age from 1990 to 2019, for 204 countries and territories. Methods: We modelled meningitis mortality using vital registration, verbal autopsy, sample-based vital registration, and mortality surveillance data. Meningitis morbidity was modelled with a Bayesian compartmental model, using data from the published literature identified by a systematic review, as well as surveillance data, inpatient hospital admissions, health insurance claims, and cause-specific meningitis mortality estimates. For aetiology estimation, data from multiple causes of death, vital registration, hospital discharge, microbial laboratory, and literature studies were analysed by use of a network analysis model to estimate the proportion of meningitis deaths and cases attributable to the following aetiologies: Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae, group B Streptococcus, Escherichia coli, Klebsiella pneumoniae, Listeria monocytogenes, Staphylococcus aureus, viruses, and a residual other pathogen category. Findings: In 2019, there were an estimated 236 000 deaths (95% uncertainty interval [UI] 204 000–277 000) and 2·51 million (2·11–2·99) incident cases due to meningitis globally. The burden was greatest in children younger than 5 years, with 112 000 deaths (87 400–145 000) and 1·28 million incident cases (0·947–1·71) in 2019. Age-standardised mortality rates decreased from 7·5 (6·6–8·4) per 100 000 population in 1990 to 3·3 (2·8–3·9) per 100 000 population in 2019. The highest proportion of total all-age meningitis deaths in 2019 was attributable to S pneumoniae (18·1% [17·1–19·2]), followed by N meningitidis (13·6% [12·7–14·4]) and K pneumoniae (12·2% [10·2–14·3]). Between 1990 and 2019, H influenzae showed the largest reduction in the number of deaths among children younger than 5 years (76·5% [69·5–81·8]), followed by N meningitidis (72·3% [64·4–78·5]) and viruses (58·2% [47·1–67·3]). Interpretation: Substantial progress has been made in reducing meningitis mortality over the past three decades. However, more meningitis-related deaths might be prevented by quickly scaling up immunisation and expanding access to health services. Further reduction in the global meningitis burden should be possible through low-cost multivalent vaccines, increased access to accurate and rapid diagnostic assays, enhanced surveillance, and early treatment. Funding: Bill & Melinda Gates Foundation. © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. **Please note that there are multiple authors for this article therefore only the name of the first 30 including Federation University Australia affiliate “Muhammad Aziz Rahman” is provided in this record**

Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019

- Wu, Dongze, Jin, Yingzhao, Xing, Yuhan, Abate, Melsew, Abbasian, Mohammadreza, Abbasi-Kangevari, Mohsen, Abbasi-Kangevari, Zeinab, Abd-Allah, Foad, Abdelmasseh, Michael, Abdollahifar, Mohammad-Amin, Abdulah, Deldar, Abedi, Aidin, Abedi, Vida, Abidi, Hassan, Aboagye, Richard, Abolhassani, Hassan, Abuabara, Katrina, Abyadeh, Morteza, Addo, Isaac, Adeniji, Kayode, Adepoju, Abiola, Adesina, Miracle, Adnani, Qorinah, Afarideh, Mohsen, Aghamiri, Shahin, Agodi, Antonella, Agrawal, Anurag, Arriagada, Constanza, Ahmad, Antonella, Rahman, Muhammad Aziz, Alif, Sheikh

  • 1